Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.
Scemblix proved more efficacious than older TKIs, but the older drugs may maintain a presence for economic reasons, though Takeda’s Iclusig may see a diminished role due to tolerability concerns.
Eli Lilly’s India chief, at a recent summit, talked about India moving up the “priority list” when it came to boardroom discussions, while the founding CEO, Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, outlined the implications for pharma as the massive publicly funded health assurance scheme widens coverage in the country.
UniQure said discussions with the FDA resulted in a path forward for seeking accelerated approval of its gene therapy AMT-130 in Huntington’s disease.
Phase II data for onvansertib in first-line RAS-mutated metastatic colorectal cancer demonstrated impressive early efficacy and underpinned a $40m fundraising for the company.
Deal Snapshot: December is just over a week old but the UK giant has packed a lot in, signing collaborations with likes of Duality Biologics (cancer) and Muna Therapeutics (neurodegeneration). Now it is targeting fibrotic diseases and osteoarthritis after inking a deal with Relation Therapeutics.
The firm said it will file the D1/D5 dopamine receptor agonist for US FDA approval in 2025. The drug may salvage value from AbbVie’s Cerevel buyout.
UniQure said discussions with the FDA resulted in a path forward for seeking accelerated approval of its gene therapy AMT-130 in Huntington’s disease.
Deal Snapshot: December is just over a week old but the UK giant has packed a lot in, signing collaborations with likes of Duality Biologics (cancer) and Muna Therapeutics (neurodegeneration). Now it is targeting fibrotic diseases and osteoarthritis after inking a deal with Relation Therapeutics.
The US election result brought stock market volatility especially to pharma and biotech companies but the poster children for approved GLP-1 agonists and vaccines were initially the hardest hit.
Eli Lilly’s India chief, at a recent summit, talked about India moving up the “priority list” when it came to boardroom discussions, while the founding CEO, Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, outlined the implications for pharma as the massive publicly funded health assurance scheme widens coverage in the country.
The US election result brought stock market volatility especially to pharma and biotech companies but the poster children for approved GLP-1 agonists and vaccines were initially the hardest hit.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Plus deals involving Mitsubishi Tanabe/Dewpoint, Lilly/Rondo, Ono/Congruence, Bristol Myers Squibb/AI Proteins and more.
Private Company Edition: Atlas Venture closed its $450m Fund XIV after some notable exits. Also, Nuvig’s $161m series B round more than triples its $47m series A from 2022, while Maze’s $115m series D fell below its prior $190m round and Antag raised an €80m ($84.7m) series A.
